Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: GregSL who wrote (2721)	11/20/1998 10:44:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

Greg, Well, we can say that Cytel didn't drop straight away even though all investors, being reverse split opponents, KNOW that it is going back to the original pre-reverse-split price and one seventh the pre-reverse-split market capitalisation. You'd think they would have all bailed out. Here is a chance for reverse split opponents to make heaps by racing over and shorting it. As soon as the Cytel quarterly report came out a few days ago, crunch, there was a drop, which is shown on the price graph, days after the reverse split was done. So now we have confounding fundamental variables entering the picture and causal relationships will be hard to deduce. So all I see with the Cytel reverse split is a struggling biotech, with a long trend line downwards and no evidence that a reverse split causes doom. So as you say, I'm not convinced. They have extremely low volume too! So I'll act on my beliefs, you act on yours and we'll all be happy. Fortunately, Techniclone's success in treating lymphoma shouldn't be slowed by the share price, whether it is $10 or 10 cents. That just affects the financial returns to existing shareholders. Maurice